Lercanidipin-Hcl Stada (Lercanidipine Hydrochloride)

• Lercanidipine hydrochloride is used to manage hypertension, a condition characterized by chronically elevated arterial pressure.
• Hypertension: reduces systolic and diastolic blood pressure, helping to lower the risk of cardiovascular events.
• Essential hypertension: provides long‑term blood pressure control in primary hypertension.
• High blood pressure: assists in achieving target blood pressure goals as part of antihypertensive therapy.

• Lercanidipine hydrochloride selectively blocks L‑type calcium channels in vascular smooth muscle. Inhibition of calcium influx prevents contraction of arterial smooth muscle, leading to vasodilation of peripheral vessels. The resulting decrease in systemic vascular resistance lowers arterial pressure, providing antihypertensive effect without significant negative inotropic activity.

Lercanidipine hydrochloride may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity, often transient.
• Flushing: sensation of warmth and redness, especially on the face.
• Peripheral edema: swelling of ankles or lower legs.
• Dizziness or light‑headedness, particularly after standing.
• Tachycardia: increased heart rate in some patients.
• Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure causing fainting.
• Myocardial infarction: rare occurrence of heart attack.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Allergic reactions: rash, pruritus, or angioedema.
• Cardiac arrhythmias: abnormal heart rhythms.
• Stevens‑Johnson syndrome: rare severe skin reaction.

• Before initiating therapy with lercanidipine, clinicians should consider several safety aspects.
• Monitor blood pressure: adjust dose based on therapeutic response.
• Avoid abrupt discontinuation: taper to prevent rebound hypertension.
• Caution in hepatic impairment: dose may need adjustment.
• Use carefully in elderly patients: increased sensitivity to hypotension.
• Avoid concomitant strong CYP3A4 inhibitors: may raise drug levels.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Lercanidipine can interact with several medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations.
• Co‑administration with other antihypertensives: risk of excessive hypotension.
• Grapefruit juice: can elevate drug exposure.
• Simultaneous use with diltiazem or verapamil: additive calcium‑channel blockade.
• Rifampicin: may reduce therapeutic effect.

Moderate Interactions (Monitor Closely)

• Diuretics: monitor electrolytes and blood pressure.
• Beta‑blockers: may require dose adjustments.
• NSAIDs: can attenuate antihypertensive response.
• Antidiabetic agents: monitor glucose control.
• Lipid‑lowering statins: observe for muscle toxicity.